Lv6
2440 积分 2023-08-25 加入
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
3小时前
待确认
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
4小时前
已完结
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
7天前
已完结
Novel Therapies for Primary Central Nervous System Lymphomas
8天前
已完结
Advances in Primary Central Nervous System Lymphoma
8天前
已完结
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges
8天前
已完结
Role of Radiotherapy in PCNSL within the Current Therapeutic Landscape: a Comprehensive Review
8天前
已完结
Primary central nervous system lymphoma: Evolving treatment strategies to achieve improved long-term disease control
8天前
已完结
Nationwide Incidence, Treatment Pattern, and Prognosis of Primary CNS Lymphoma in Taiwan, 2012–2020: A Retrospective Cohort Study
9天前
已关闭
A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma
14天前
已完结
皖公网安备34019202002308
